A person working on international cooperation in Chinese medicine told reporters that at this stage, Chinese pharmaceutical exports to the US are still mainly raw materials, while innovative drugs are mainly based on trade in services, and generic drug exports fall behind in relative share. “It should be noted that the global market, especially the US pharmaceutical market, relies on Chinese APIs that are difficult to replace in the short term; otherwise, drug prices will skyrocket and be in short supply. However, there is also some pressure on generic drug products exported to the US. Although it is manageable in the short term, it is under pressure in the medium to long term.” The source also believes that there are time differences and variables in the implementation of the US tax increase policy. Judging from the time difference, the policy presupposes that levies will not be planned until the end of two years from August 1, 2026, leaving a buffer for companies to respond next. Judging from the variables, policy may fluctuate with the US Internal Affairs Bureau.

A person working on international cooperation in Chinese medicine told reporters that at this stage, Chinese pharmaceutical exports to the US are still mainly raw materials, while innovative drugs are mainly based on trade in services, and generic drug exports fall behind in relative share. “It should be noted that the global market, especially the US pharmaceutical market, relies on Chinese APIs that are difficult to replace in the short term; otherwise, drug prices will skyrocket and be in short supply. However, there is also some pressure on generic drug products exported to the US. Although it is manageable in the short term, it is under pressure in the medium to long term.” The source also believes that there are time differences and variables in the implementation of the US tax increase policy. Judging from the time difference, the policy presupposes that levies will not be planned until the end of two years from August 1, 2026, leaving a buffer for companies to respond next. Judging from the variables, policy may fluctuate with the US Internal Affairs Bureau.